

PRESSURE BIOSCIENCES INC

Form 8-K

November 18, 2013

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2013

PRESSURE BIOSCIENCES, INC.  
(Exact name of registrant as specified in its charter)

Massachusetts (State or other jurisdiction of incorporation)	000-21615 (Commission File Number)	04-2652826 (IRS Employer Identification No.)
--	--	--

14 Norfolk Avenue  
South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

I t e m

2.02. Results of Operations and Financial Condition.

The Company presented at the SeeThruEquity Investor Conference in New York City on November 12, 2013. The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 2.02 as if fully set forth herein.

On November 18, 2013, the Company issued a press release announcing business and financial updates. A copy of the release is furnished herewith as Exhibit 99.2.

The information contained in this Current Report, including Exhibits 99.1, 99.2 are being furnished and not filed pursuant to this Item 2.02 of Form 8-K. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item

9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
<u>99.1</u>	Company information – “Power Point Presentation” dated November 12, 2013 (filed herewith).
<u>99.2</u>	Press Release, dated November 18, 2013, relating to Pressure BioSciences’ financial results (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

Date: November 18, 2013

By: /s/ Richard T. Schumacher  
Richard T. Schumacher  
President and Chief Executive  
Officer